The following is my market assessment for the quarter. I have tried to simplify it as much as
possible. However, market conditions are
unprecedented in our era, and there is much to consider when balancing your
portfolio. This report has been pit together
based on information provided by our own fund managers.
The key points of note pertain to the effects of the pandemic on
the global economy. The Delta variant
now makes up most of new cases globally. Since the start of July, the global effective
reproduction number has been north of the 1.0 threshold and climbing steadily
upward, indicating the spread of COVID-19 is back to exponential growth. Regardless, current economic recovery remains
highly policy driven, especially with Delta infections likely to extend the
progress of reopening and the uncertainty around the variant continues to weigh
on market sentiment. At the moment, relative
valuation continues to favour equities over bonds and debt instruments, and the
gap has widened given lower Treasury yields and improving earnings. I expect this to ease as the Federal Reserve
becomes hawkish on inflation, and raise interest rates. At the moment, inflation in the US is 4.2%,
which is well above their 2% threshold.
In the last quarter, all funds underperformed the benchmark due to the
volatile market. The market rotated from
growth to value stocks in that period, and will take time to catch up. However, since inception, all the funds have
outperformed their respective benchmarks due to a higher asset allocation
towards equities.
The Delta variant now makes up most of the new cases globally. While the spread of COVID-19 is back to
exponential growth, both hospitalisation and fatality rates appear to be
manageable compared to previous waves, for countries with high vaccination
rate. As such, there is no reason to
expect the global economy to return to the tight lockdowns we saw back in March
and April 2020. Governments are incentivised
to accept gradual lifting of restrictions even though cases continue to climb.
Economic recovery remains on track in major economies despite
market expectations are adjusting from elevated levels. The service sector is recovering strongly at a
global level thanks to the combined efforts of easing social distancing
measures, active policy support, and vaccine rollout globally. Additionally, with solid manufacturing
activity, this should lead to strong economic growth in the remainder of the
year, supporting the prospects of risk assets. Inventories will be restocked when supply-chain
disruptions are eased, providing additional tailwind to activity. China is expected to be an exception among the
major economies due to strict lockdown of provinces where there are cases. The same applies to Hong Kong. With China’s growth slowdown, its first mover
advantage is fading when the cycle matures. Recent policy actions should alleviate some of
the concerns. Overall, since vaccines
are still highly effective in reducing severe COVID-19 illness and fatalities,
countries with high vaccination rates should see a clear divergence in economic
performance and inflation trajectory compared to those with low vaccination
rates. Vaccinations remain key to the
broader reopening process.
Inflationary concerns have receded over the past couple of months. Inflation is elevated only in a few countries,
and in the case of the US, it is mostly concentrated in goods and services
sensitive to COVID-19 and the subsequent reopening of the economy. In China, producer price inflation has likely
peaked on the back of stabilising commodity prices, while consumer prices
remain benign. Therefore, anticipated rapid
rise in inflation prints is likely transitory in nature.
On company fundamentals, Q1 earnings season ended on a high note
with over 85% of S&P 500 constituents reported earnings surprise. The strong momentum looks to be carried on
into Q2/ Out of the companies reported
earnings so far, the magnitude of surprise is also stellar at near 20% on
average. Additionally, we can reasonably
anticipate strong share repurchase activities for this year, with the announced
share buyback so far beating the last 3-year average in the US markets. These factors would provide additional
tailwinds to developed market equities going forward under this ample liquidity
environment.
The outlook for Asian equities is less rosy for the moment. Chinese equities continue to soften on the
back of rising uncertainty from the regulatory scrutiny over key sectors. Additionally, there is a fear of cascading
corporate debt default lead by the impending collapse of Evergrande Group. Although the ongoing structural reforms of
capital markets could be positive to the markets in the long run, investors are
pricing in a higher risk premium in the near term. Outside of China, in major ASEAN markets
barring Singapore, sentiments are largely weighed by the renewed COVID-19 infections from Delta combined with relatively low vaccination rates in these
economies. Meanwhile, momentum in
Taiwanese and Korean equities is receding as the upcycle in electronics and
chips manufacturing is gradually priced in.
The current recovery remains highly policy driven, especially with
Delta infections likely to extend the progress of reopening and the uncertainty
around the variant continues to weigh on sentiment. Policymakers will have to keep accommodative
policies for some more time. Managing
the transition between ultra-loose economic policies and a sustainable setting
continues to be the focus of the markets.
The Federal Reserve continues to maintain its accommodative stance. Jerome Hayden Powell, 16th chair of
the Federal Reserve, reiterated the view that recent inflationary pressures are
likely to prove transitory and acknowledged that the Fed will continue its
discussions about tapering in coming meetings with “advance notice” on any
tapering decision. Similarly, the
European Central Bank (ECB) remains its dovish stance with no sign of
moderation in Pandemic Emergency Purchase Programme (PEPP) purchases and
expects interest rates to remain at their present or lower levels until
inflation reaching 2% well ahead in their forecast horizon of 2 to 3 years.
In Asia Pacific, there have been some notable changes to central
banks’ stance. Notably, the Peoples Bank
of China (PBoC) surprised the markets with an unexpected cut in reserve
requirement ratio (RRR) in July, and future policy guidance is expected to be
on the dovish side as the recovery continues.
Apart from the Delta infections and the idiosyncratic risks in Asia and
China as briefly mentioned above, I am cognisant of the other risks in the
system. These risks should not derail
the overall direction of relative performance between equities and fixed
incomes, and within equities, developed markets versus East Asia and emerging
markets.
For this quarter, fixed income allocation has the following focus. Treasury yields declined recently on the back
of reduced inflation compensation. The
eventual path tapering of asset purchases should put a dampener on Treasury
performance. With US investment-grade
default rates below historical averages, downside risk remains low. However, limited upside for US investment-grade
credit is expected, given the tight spread range and its higher sensitivity to
interest rate movements. Comparatively,
Asian credit remains more attractive as spreads widened while default risks
appear to remain stable. Spillover risks
from certain distressed Chinese corporates remain contained.
Equities to continue to perform reasonably well against bonds. More specifically global equities should
continue their run relative to fixed income, likely driven by developed
markets. Major central banks remain
accommodative for the time being, with any tapering discussion appearing to be
well communicated with the markets. In
the US, reported earnings and sales continue to surprise on the upside with
magnitude trending upward. Strong
buyback activities likely provide additional tailwinds. Within equities, I am cautiously neutral on
Asian equities given the region-specific headwinds including China’s regulatory
scrutiny and low vaccination rates in ASEAN countries, except Singapore.
Concerns surrounding the Delta variant remains our focus as
governments are attempting to adapt to the new normal of living with the
endemic COVID-19. Relative valuation
continues to favour equities over bonds and credits, and the gap has widened
given lower Treasury yields and improving earnings. Agility on adding or trimming equity in
correction or for profit taking is necessary to balance the return potential
against risks. The factors driving
recent weakness in Asian equities, could potentially provide a good entry point
in the region.
While our investments are all made with a long-term outlook, our
portfolio performance has been delivering positive returns since inception. There have been mixed results in the short
term, but as the market turns, they will balance out, since the emphasis is on
the long-term investment horizons. During
the quarter, our funds have continued to remain overweight to equities for the
Adventurous, Balanced and Conservative Funds, adding to the outperformance
since inception. The global recovery is stemming
from the flood in liquidity through fiscal and monetary policies. The lifting of lockdown restrictions around
the world is still very much on track even after the recent two months of
rising Delta infections. New waves of
infections from further coronavirus mutations will only delay the recovery, but
not completely derail the reopening narrative.
Global and regional economies cannot afford to remain closed.
Baillie Gifford’s Iain McCombie, sub-manager of the AIA Global
Quality Growth Fund, shared his views on stock picking fundamentals, the
macroeconomic environment, and short-term volatility.
Baillie Gifford has a long-term
growth investment thesis for the AIA Global Quality Growth Fund. What are the advantages of this strategy in
the current cycle?
The environment this year provides
strong evidence for why a strategy based on market timing and economic
forecasting is fraught with challenges. At
the beginning of this year, “re-opening” stocks came into vogue as the
expectations of a strong and sharp economic recovery gathered pace. As the number of COVID-19 cases has spiked
again, the shine has been taken off these re-opening beneficiaries in favour of
more defensive names. It would be
fantastic if we could accurately predict the see-sawing of the market between
these two poles, but we think that it would be near impossible to do
consistently. Instead, we seek to own a
small number of the world’s most exceptional growth companies. These are structurally advantaged businesses
with differentiated cultures and large markets to grow into.
Ultimately, portfolio positioning is
driven by our bottom-up stock picking and is reflective of where we are
currently finding the most attractive growth opportunities on a 5-10 year view.
Key portfolio themes that emerge would
include: climate and the energy transition, the opportunity in innovative
healthcare, and the new wave of technology companies supporting
entrepreneurship by offering “scale as a service” – this includes companies
like Amazon Web Services, Shopify and Twilio which are helping to level the
playing field between the largest and smallest, essentially lowering the
barriers to entrepreneurship.
What are the key risks that might
derail your long term growth investment thesis?
There is a lot of time and effort
spent by market commentators on the likely risks created by rising interest
rates and inflation. Higher rates have
traditionally been bad for equities, and growth equities in particular, because
a larger proportion of their earnings lie further into the future, so a higher
discount rate means a lower present value.
However, within the Global Quality
Growth Fund we would highlight a clear preference for companies with strong
balance sheets - many holdings have net cash, pricing power and a market
leadership position which should, on average, leave them better positioned than
rivals in this type of environment. For
example, software businesses that operate subscription models rather than
one-time only charges, and companies like Alibaba, Netflix and Amazon have
illustrated that their customers stick with them even when they put prices up.
So, we are pretty relaxed about the
potential for a modest uptick in rates and inflation going forward. The main reason we are unconcerned is that we
are much more interested in how the world might look a decade in the future. We are currently seeing a level of economic
disruption that perhaps only presents itself once a century, so if our vision
of the world in the 2030s is even close to correct – a world where there is
abundant clean energy, where vast amounts of data is thrown off by innumerable
connected devices, and where technology and healthcare collide to significantly
improve the quality of people’s lives – then a bit of near-term inflation will
seem insignificant in the context of the long term gains we can make for
clients by looking past seemingly high near term valuations and investing
around these structural megatrends.
What are some of the recent
portfolio developments and the rationale behind them?
Perhaps one of the most exciting
themes emerging in the portfolio at the moment is in healthcare. Some have predicted that the 21st century
will be the century of biology, as our increasing ability to analyse and
understand human diseases at the genetic level leads to a transformation in
medicine. This potential exploded into
the public consciousness during 2020 with the rapid development of COVID-19 vaccines. Famously, it took Moderna, which
is not held in the Global Quality Growth Fund, just four days to create its
version: two days for Illumina, a longstanding holding in the Fund, to sequence
the coronavirus genome, then two days for Moderna to apply its technology to
the problem.
We firmly subscribe to the view that
we are on the cusp of something quite extraordinary in healthcare and the Fund
has been gradually increasing its exposure in this area. Alongside current holdings Illumina, Staar
Surgical and Denali Therapeutics, we have recently taken a new position in 10X
Genomics, which develops instruments and consumables for the analysis of single
cells, and added to the holding in Exact Sciences, which offers molecular
cancer diagnostic tests. We also own
firms looking to improve the efficiency of new drug discovery and development,
such as Dassault Systèmes, a software company that helps with the design and
development of new products, and Codexis, a protein engineering company that
creates custom enzymes.
Since our clients are mostly Asia
based, how does Billie Gifford identify companies with high quality growth
potential in the long run given the idiosyncratic differences from this side of
the world?
At Baillie Gifford, we have been
investing across the globe since our inception in 1908. Indeed, our very first investments as a firm
were in the rubber plantations of Malaysia, predicated on the growth of the car
industry in the US. The key point being,
as investors, we have always retained a global outlook in our approach, married
with a willingness to remain open-minded to different business models and
consumer preferences emerging from different parts of the world.
A case in point is China. Many investors have and continue to view China
largely through a Western prism. How
often have we heard the descriptions: “Alibaba is the Amazon of China” and
“Meituan is China’s Grubhub”? The danger
with these lazy comparisons is that firstly they ignore the scale differences
between the US and China, but they also infer that these are copycat
businesses. The reality, however, is
that many of China’s internet businesses are leading rather than lagging on the
innovation front. The deep relationships
we have been able to build with companies across Asia over the past few decades
has helped immensely in educating us on these rapid developments and cultural
differences.
In addition, the emphasis we place
on alternative sources of information in our research process has also been
hugely helpful. Rather than relying on
traditional, financial sources of information which are typically short-term
and US and Europe centric, we have spent the last couple of decades cultivating
alternatives that we believe help us to see the world differently, expand our
horizons, and help us generate value for clients. Within China, as an example, these
relationships span industrial and market experts but also experts within
academia. We sponsor the University of
Oxford’s China Centre and have developed a relationship with Tsinghua
University’s Computational Biology Department. We are also continuing to grow and develop our
own Shanghai investment research office. Having an on-the-ground presence will help to
deepen existing relationships with companies we own, get closer to exciting
growth companies of the future, and provide a cultural lens to enhance and
challenge existing perspectives.